BACKGROUND: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. PATIENTS AND METHODS: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. RESULTS: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. CONCLUSIONS: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.
BACKGROUND: To evaluate the activity of CAP regimen in advanced salivary gland carcinomas. PATIENTS AND METHODS: Twenty-two patients with advanced salivary gland carcinomas were treated according to the CAP regimen. All patients were previously treated with surgery and/or radiotherapy and/or chemotherapy. Seven patients had local or locoregional disease, nine patients had local and metastatic disease, six patients had metastatic disease only. The most common histologies were included. RESULTS: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival time for the entire series was 21 months. CONCLUSIONS: In this investigation, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination therapy.
Authors: Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao Journal: Cancer Cytopathol Date: 2020-05-18 Impact factor: 5.284
Authors: Aaron W Pederson; Joseph K Salama; Daniel J Haraf; Mary Ellen Witt; Kerstin M Stenson; Louis Portugal; Tanguy Seiwert; Victoria M Villaflor; Ezra E W Cohen; Everett E Vokes; Elizabeth A Blair Journal: Head Neck Oncol Date: 2011-07-26
Authors: Felipe Nör; Kristy A Warner; Zhaocheng Zhang; Gerson A Acasigua; Alexander T Pearson; Samuel A Kerk; Joseph I Helman; Manoel Sant'Ana Filho; Shaomeng Wang; Jacques E Nör Journal: Clin Cancer Res Date: 2016-08-22 Impact factor: 12.531
Authors: N Chooback; Y Shen; M Jones; K Kasaian; M Martin; T Ng; T Thomson; M Marra; J Laskin; C Ho Journal: Curr Oncol Date: 2017-06-27 Impact factor: 3.677